Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Histologically confirmed aggressive lymphomas,~* Patient requires treatment because NHL relapses~* Measurable disease~* Recovery from any non-hematological toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade \< 2 symptomatic peripheral neuropathy is allowed.~* Age \> 18 years.~* Performance status (ECOG) \< 2~* Adequate renal, hepatic, and bone marrow function (assessed \< 14 days before inclusion in the study)~* Left ventricular ejection fraction within normal limits.~Exclusion Criteria:~* Prior therapy with Aplidin®.~* Concomitant therapy with any anti-lymphoproliferative agent~* Acute lymphoblastic leukemia.~* CNS lymphoma.~* HIV-associated lymphoma.~* Prior gene therapy with viral vectors.~* More than three previous lines of systemic biological agents or chemotherapies. Wash-out periods since the end of the precedent therapy less than:~  * 6 weeks for nitroso-urea or high dose chemotherapy~ * 3 weeks for other chemotherapies or biological agents~ * 4 weeks for radiation or radionuclide therapy (6 weeks in case of prior extensive external beam radiation (more than 25% of bone marrow distribution).~ * 4 weeks for major prior surgery~ * 30 days for any investigational product~ * 4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell transplantation.~* Pregnant or lactating women.~* Men and women of reproductive potential who are not using effective contraceptive methods~* History of another neoplastic disease. Exceptions: Non-melanoma skin cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no evidence of disease for at least 10 years.~* Known cerebral or leptomeningeal involvement.~* Other relevant diseases or adverse clinical conditions~* Treatment with any investigational product in the 30 days period before inclusion in the study.~* Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol~* Limitation of the patient's ability to comply with the treatment or follow-up protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm One (Type: EXPERIMENTAL): Aplidin® given as a 1-hour weekly IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).